JPMA’s Teshirogi Talks About Challenges Facing Japan Pharma
This article was originally published in PharmAsia News
During an event in New York, the president of the Japan Pharmaceutical Manufacturers Association spoke about the troubles facing the Japanese pharmaceutical industry and the steps that need to be taken to continue competing on a global level. He also addressed the changes happening at the company he heads, Japan’s Shionogi.
You may also be interested in...
Full data from the Phase III SPRING-2 trial released at the International AIDS Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.